Abstract: Background: Laryngeal cancers affect one quarter of all head and neck cancers. Chemotherapy is a standard method in treatment laryngeal carcinoma. However, cancer chemotherapy is often a failure due to the appearance of drug resistance. This fact suggests that the search for novel, safe, and more effective laryngeal cancer drugs are required. Antimycin A 3 is a fit ligand of anti-apoptotic Bcl-2. While Bcl-2 is known to be over-expressed in laryngeal cancer cell, it is quite reasonable to expect antimycin A 3 and its analogue to induce apoptosis in those cells.
INTRODUCTION
Laryngeal cancer is a significant entity of oncology. Approximately it causes 30% to 40% of all head and neck malignancies. The highest incidence of laryngeal cancer happens between the fifth and seventh decade of life. Several predisposing factors have been reported, the most important ryngeal cancer also varies depending on the region, with an increasing trend worldwide. For the year 2004, 89,000 deaths from cancer of the larynx in men and 12,000 in women are reported worldwide [2] .
In Indonesia, the annual mortality rate per 100,000 population from larynx cancer has increased by 31.6 % since 1990, an average of 1.4 % a year. Cigarette-smoking and dietary risk were thought to be responsible for larynx cancer in Indonesia population during 2013 [3, 4] . Chemotherapy is a standard method in treatment laryngeal carcinoma. However, cancer chemotherapy is often a failure due to the appearance of drug resistance [5] . High mortality rate of larynx cancer in Indonesia along with developing of drug resistance has prompted us to search and discover novel laryngeal cancer drugs that are safer and more effective.
Antimycin A 3 ( Fig. 1) , a nine-membered dilactone derived from Streptomyces sp., is an active agent that prevents the electron transfer activity of ubiquinol-cytochrome c oxidoreductase and inhibit the growth of human cancer cells [6] [7] [8] . Antimycin A 3 interacts with the Bcl-2 homology domain 3 (BH3)-binding hydrophobic groove of Bcl-X L . Antimycin A 3 and BH3 peptide both induce mitochondrial swelling and loss of mitochondrial membrane potential. These changes might follow the opening mitochondrial permeability transition pores. The Bcl-2 stabilized mitochondrial membrane has potential in induced cells to undergo apoptosis. In the absence of Bcl-2, apoptogenic factors such as cytochrome c and apoptosisinducing factor (AIF) are released from mitochondria. Aberrant overexpression of antiapoptotic members of the Bcl-2 protein family leads to malignant transformation and subsequent resistance to anticancer agents [9, 10] .
Antimycin A 3 is a fit ligand of anti-apoptotic Bcl-2.While Bcl-2 is known to be expressed in laryngeal cancer cells [5, 11] , it is quite reasonable to expect antimycin A 3 and its analogue to induce apoptosis in those cells. With this viewpoint, we decided to conduct research that is aimed to evaluate cytotoxicity of the synthesized openchain analogues of antimycin A 3 ( Fig. 1) against HEP-2 laryngeal cancer cells, as well as to conduct in silico study of the analogues on receptor binding target Bcl-2 of laryngeal cancer. Open-chain analogue 1 and 2 used in this work ( Fig. 1) have been successfully synthesized in our recent research in 2015, which showed potent anticolorectal cancer activity on HCT-116 cells [12] . Previously, in 2010, we have reported the synthesis of 2-hydroxynicotinoyl-serine-butyl esters related to antibiotic UK-3A which showed a strong inhibitory activity against Bacillus subtilis and Staphylococcus aureus [13] . In 2012, we have succeeded in synthesizing 18-membered analogue of antimycin A 3 which demonstrated a strong cytotoxicity against HeLa cells, Breast MDA-MB-231 cells and prostate PC-3 cells [14] . In 2014, we have simulated some antimycin A 3 analogues as inhibitors of anti-apoptotic Bcl-2 of breast cancer by in silico molecular docking [15] . In this work, as our continuing research to discover potential antibiotic anticancer agents, we focused on the in silico study and cytotoxicity evaluation of the synthezid open-chain analogues of antimycin A 3 against HEP-2 laryngeal cancer cells. 
MATERIALS AND METHODS

Synthesis
Design and synthesis of the open-chain analogue 1 and analogue 2 have been reported in our previous work [12] , as outlined in Scheme 1. The preparation of 1 and 2 started from 8. In this case, coupling of 8 with allyl bromide under basic condition as reported by Wu et al. [16] , proceeded smoothly to give 7. Boc deprotection of 7 followed by amidation with acid 6 provided 5. Treatment of 5 with Sharpless reagent in the presence of (DHQ) 2 PHAL and (DHQD) 2 PHAL yielded corresponding hydroxylated amide 3 and 4 respectively, with diastereomeric ratio (dr) 10:1. Removal of the Bn group from 3 and 4 with H 2 and Pd/C followed by purification with medium pressure liquid chromatography completed the synthesis of analogue 1 and 2 in good yield. The synthesis procedure of compound 7, amide 5, hydroxylated amide 3, hydroxylated amide 4, analogue 1 and 2 has been described in our previous work [12] .
Experimental Data
1 H NMR and 13 C NMR spectra were recorded on 500 MHz JEOL JNM-ECP500 spectrometers using tetramethylsilane ( 0), CDCl 3 ( 7.26), DMSO ( 2.49) or acetone ( 2.05) as an internal standard. Mass spectra were recorded on Shimadzu GCMS QP-5000 or JEOL JMS-AX 700 spectrometers. 
Compound 7
In Silico Study
In this research, we simulated open-chain analogue 1 and 2 based on their interactions with Bcl-2 using computer software applications (Molecular method) [17] to determine the best compounds [18] . Analysis and screening were based on Gibbs Free energy ( G) values, affinity, conformation of the structure, and hydrogen bonding interaction between compounds and the target proteins [19] .
Sequence Alignment and Homology Modelling
Target protein sequences were selected and downloaded From NCBI (http://www.ncbi.mlm.nih.gov/ genomes//). The multiple sequence alignment method was based on clustal W2 program (www.ebi.ac.uk/Tools/clustalw2/index.html). Homology modeling was performed using the Swiss Model which can be accessed through http://www. swissmodel.expasy.org/SWISS-MODEL.html. Swiss model showed that NS5B is structurally homologous to a target protein with template PDB code 1g5mA (target region 3-204, 88.00 % of sequence identity.
Structural Analysis of Target Protein
Validation of 3D structure from homology modeling was performed using the Protein Geometry program and superimposed using superpose program in MOE 2009.10 software. Based on superimposed the RMSD was calculated to find out structural similarity between template model mutated with 3D structure from homology modeling. Identification of binding site of protein target was conducted by using site finder program in MOE 2009.10 software.
Optimization and Minimization of 3D Structure
Optimization and minimization of threedimensional structure of Bcl-2 were conducted using the software of MOE 2009.10. with addition of hydrogen atoms. Protonation was employed with protonate 3D programs. Furthermore, partial charges and force field were employed with MMFF94x. Solvation of enzymes was performed in the form of a gas phase with a fixed charge, RMS gradient of 0.05 kcal/A 0 mol, and other parameters using the standard in MOE 2009.10 software.
Preparation of Compounds
Antimycin A 3 analogues were designed using ACD Labs software. With this software, the analogues were built into three-dimensional structures. The three-dimensional shape was obtained by storing the derivative in the 3D viewer in ACDLabs. Furthermore, the output format was changed into Molfile MDL Mol format using the software Vegazz to confirm for the docking process. Compounds were in the wash with compute program, adjustments were made with the compound partial charge and partial charge optimization using MMFF94xforcefield. The conformation structure energy of compounds was minimized using the RMS gradient energy with 0,001 kcal/A o mol. Other parameters were in accordance with the default setting in the software.
Molecular Docking
The docking process started with the docking preparation using a docking program from MOE 2009.10 software. Docking simulations were performed with the Compute-Simulation dock program. The placement method was conducted using a triangle matcher with 1.000.000 repetition energy reading for each position and other parameters were in accordance with the default settings in the MOE software. Furthermore, scoring functions used London DG, refinement of the configuration repetition forcefield with 1.000 populations. The first repetition was done for 100 times and the second setting was conducted only for one of the best results.
In Vitro Cytotoxicity Assay
Cytotoxicity evaluation of the synthesized products was carried out in Department of Anatomical Pathology Department, Faculty of Medicine, University of Indonesia. The tested laryngeal cancer Hep-2 cells are the culture collection of Anatomical Pathology Department, Faculty of Medicine, University of Indonesia. MTT assay [20, 21] was performed to measure the antiproliferation effects of synthesized amide 5, amide 3, amide 4, analogue 2, analogue 1 and the original antimycin A 3 on the laryngeal cancer Hep-2 cells. Synthesized amide 5, amide 3, amide 4, analogue 2, analogue 1 and antimycin A 3 were diluted and added to target cells in triplicates with final concentrations at 51.2, 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4 Fg/ml. The cells were incubated for 48 hours and 20 Fl of 5 mg/ml solution of MTT in phosphate-buffered saline (PBS) was added to triplicate samples and the plates were incubated for additional 4 hours. The plates were then centrifuged and the medium was removed. Two hundred microliters (200 Fl) of DMSO was added to each well to dissolve the purple blue sediment, the absorbance was determined at 590 nm on a microplate reader (Model 550, Bio-Rad, USA). The inhibition rate can be calculated as follows:
Inhibiton rate (%) = 1 -(absorbance of treatment group/absorbance of control group) x 100%.
The 50% inhibitory concentrations (IC 50 ) of the 48 hours were calculated with Bliss assay.
RESULTS AND DISCUSSION
In silico Study
Lipinski's rule based on the measurement of Gibbs energy ( G value), affinity (pKi), a number of hydrogen (H) donor and hydrogen (H ) acceptor, was utilized for in silico study of analogue 1, analogue 2 and antimycin A 3 . The results are summarized in Table 1 .
As shown, analogue 1 and 2 which have G value lower than antimycin A 3 on binding targets Bcl-2, showed a higher stability than antimycin A 3 . pKi value of analogue 1 and 2 is higher than pKi Ligand complex interaction of antimycin A 3 , analogue 1 and analogue 2 with Bcl-2 are displayed in Fig. (2) . Stability and affinity of the ligand complex with the active site was influenced by the bond distance and complex score. As shown in the figures and tables, analogue 1 and analogue 2 could change the conformation of all receptor target cavity, or in other words, it is able to enter the binding site of receptor target Bcl-2 of laryngeal cancer. Thus, the analogues have a stronger inhibitory activity on Bcl-2 of laryngeal cancer than antimycin A 3 . These in silico docking suggest that it is quite possible to expect analogue 1 and analogue 2 as a potent and superior synthetic laryngeal cancer drugs.
Cytotoxicities of the Analogues
MTT cell proliferation assay was applied to determine the cytotoxicity of antimycin A 3 , analogue 1, and analogue 2 on lary ngeal HEP-2 cells. The data are reported in Table 2 . Cytotoxicity is expressed by IC 50 . The smaller the IC 50 value, the stronger the anticancer activity.
As shown in Table 1 , amide 5 with IC 50 over 100 M showed no cytotoxicity against Hep-2 cells. In contrast to amide 5, the amide 3 and amide 4, which have two additional hydroxyl groups, showed improvement in cytotoxicity with concentration 59.3 M and 84.8 M against Hep-2 cells, respectively. The cytotoxicity of amide 3 and amide 4 was greatly improved by the presence of hydroxyl groups compared to that of amide 5. This fact suggested that the hydroxyl groups are very important for the anti-laryngeal cancer activity. Compared to amide 4, amide 3 which posses hydroxyl group with bottom facial stereochemistry, showed stronger cytotoxicity, indicating that introduction hydroxyl group with bottom facial stereochemistry was potentially responsible for increase in its anticancer activity. Furthermore, compared to amide 3 and amide 4, analogue 1 and analogue 2, which have hydroxyl group instead of benzyloxy group on 3-formamidosalicylyl moiety, showed greater cytotoxicity, suggesting that the presence of hydroxyl group on 3-formamidosalicylyl moiety in both analogue 1 and analogue 2 is very necessary to These results indicated that modifying the nine-membered dilactone core of antimycin A 3 with a hydroxylated openedchain moiety in analogue 1 and analogue 2 successfully improved its anticancer activity.
Thus, analogue 1 and analogue 2 which strongly inhibited the growth of Hep-2 cells, should be considered as a promising candidate for the treatment of human laryngeal cancer.
CONCLUSION
Opened-chain analogues of antimycin A 3 have been synthesized from Boc-L-threonine through esterification, amidation and Sharpless asymmetric dihydroxylation. Consistent with in sillico study, analogue 1 and analogue 2 showed greater anticancer activity against laryngeal HEP-2 cells as compared to the original antimycin A 3. .
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